Improved Protease Inhibitor Therapy for AIDS
1 R43 CA68999-01,
Our company will formulate a protease inhibitor, KNI-272, to improve bioavailability following oraladministration. This will be accomplished using patented technology to convert this nearly water-insspherical, amorphous, uniformly-sized submicron particles suspended in a biocompatible aqueous mediuhas been used to produce formulations for anti-cancer and antimicrobial therapy with improved oral bformulation of KNI-272 will be subjected to preliminary bioavailability evaluations in mice to demonPhase II objectives will focus on preclinical efficacy and toxicity studies following oral administrbenefits of intravenous administration. In Phase III, clinical trials will be carried out.
Small Business Information at Submission:
Principal Investigator:Michael Violante
Sts Duotek, Inc.
336 Summit Point Drive Henrietta, NY 14467
Number of Employees: